NcodiN | $18,456,480 | (Nov 21, 2025)
Voio | $8,600,000 | (Nov 21, 2025)
Stuut | $29,500,000 | (Nov 21, 2025)
PlateletBio
United States
- Watertown, Massachusetts
- 04/11/2021
- Series B
- $75,500,000
PlateletBio is the only allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a completely new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a superior cell therapy empowered to tackle previously unmet medical challenges.
- Industry Biotechnology Research
- Website https://www.plateletbio.com/
- LinkedIn https://www.linkedin.com/company/platelet-biogenesis/about/
Related People
Sam RastyFounder
United States -
Greater Boston
Biotech CEO with 25+ years of experience in leadership roles of increasing responsibility spanning global large pharma, mid-cap pharma and small, private biotech. Success in start-up company formation and launch, strategy formulation, fund raising, operations, R&D, manufacturing, corporate development, BD&L and M&A. Strategic and operational leader with product development experience in multiple therapeutic areas and technology platforms spanning small molecules to biologics to more complex gene and cell therapies.
Made Card | $8,000,000 | (Nov 21, 2025)
Poly(US) | $8,000,000 | (Nov 21, 2025)
Runlayer | $11,000,000 | (Nov 21, 2025)
AI Proteins | $41,500,000 | (Nov 21, 2025)
Automat | $15,500,000 | (Nov 21, 2025)
EQORE | $1,700,000 | (Nov 21, 2025)
Poppy Flowers | $2,700,000 | (Nov 21, 2025)
WellBeam Inc | $10,000,000 | (Nov 21, 2025)
Revenium | $13,500,000 | (Nov 21, 2025)